Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance

International Journal of STD and AIDS

Volumn 19, Issue 11, 2008, Pages 780-781

  Bhattacharya, Debika ^a,b,c   Katzenstein, D ^a   Wong, A ^d   Israelski, D ^a,b   Imperial, J C ^a,b   Keeffe, E B ^a   Donovan, R M ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b San Mateo Clinical AIDS Program   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Hepatitis B drug resistance; Hepatitis B infection; Highly active antiretroviral therapy; HIV infection; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATION; PRIORITY JOURNAL; VIREMIA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL AUDIT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED;

EID: 55849125437     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008020     Document Type: Article

References (10)

1. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005;19:221-40
2. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-19
3. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22
4. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-59
5. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6
6. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-901
7. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006;20:863-70
8. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003;17:1649-57
9. Vierling JM. The immunology of hepatitis B. Clin Liver Dis 2007;11:727-59
10. Rector WG Jr, Govindarajan S, Horsburgh CR Jr, Penley KA, Cohn DL, Judson FN. Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. Am J Gastroenterol 1988;83:262-6